کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5729590 | 1610727 | 2017 | 7 صفحه PDF | دانلود رایگان |
ObjectiveTo assess the additive effect of sildenafil citrate to tamsulosin in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia (LUTS/BPH) in men with or without erectile dysfunction (ED).Patients and methodsIn all, 150Â men with untreated LUTS/BPH with or without ED were randomised to receive sildenafil 25Â mg once daily (OD) or placebo OD (night time) combined with tamsulosin 0.4Â mg OD (day time) for 6Â months. Changes from pre-treatment scores in International Prostate Symptom Score (IPSS), IPSS-quality of life (QoL) score, maximum urinary flow rate (Qmax), and the five-item version of the International Index of Erectile Function questionnaire (IIEF-5) were assessed at 3 and 6Â months. Safety profiles were assessed by physical examination and monitoring clinical adverse events.ResultsGroup A comprised of men who received tamsulosin and sildenafil (75Â men), whilst those in Group B received tamsulosin and placebo (75). The IPSS was significantly improved in Group A compared to Group B, at â29.3% vs â13.7% (PÂ =Â 0.039) at 3Â months and â37% vs â19.6% (PÂ =Â 0.043) at 6Â months after treatment. Qmax significantly improved in both groups compared with before treatment (PÂ <Â 0.001). The IIEF-5 scores improved more in Group A than in Group B, at 58.7% vs 11.7% at 3Â months and 62.4% vs 12.4% at 6Â months after treatment (both PÂ <Â 0.001).ConclusionSildenafil citrate combined with tamsulosin improved LUTS, erectile function, and patient QoL more than tamsulosin monotherapy with the merit of a comparable safety profile in patients with LUTS/BPH.
Journal: Arab Journal of Urology - Volume 15, Issue 1, March 2017, Pages 53-59